Vir Biotechnology reported second quarter 2026 financial results on August 5, 2026. The company recognized $238.9 million in license and collaboration revenue, primarily from a $240.0 million upfront payment received from Astellas. Net income was $80.1 million, or $0.48 per share basic, compared to a net loss of $111.0 million in the prior year period. Cash, cash equivalents, and investments totaled approximately $1.01 billion at quarter-end. The company closed its global strategic collaboration with Astellas for VIR-5500 and initiated additional Phase 1 dose-expansion cohorts for this prostate cancer candidate. Topline data from the Phase 3 ECLIPSE 1 trial for chronic hepatitis delta is expected in Q4 2026, while ECLIPSE 2 and 3 data are expected in Q1 2027. Vir Biotechnology operates as a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases and cancer.

Jason O'Byrne, Executive Vice President and Chief Financial Officer, will step down from Vir Biotechnology, Inc. effective August 3, 2026, to pursue another opportunity. Brent Sabatini, current Senior Vice President and Chief Accounting Officer, has been appointed as interim principal financial officer effective August 3, 2026. Vir Biotechnology, Inc. is a biotechnology company focused on developing and commercializing infectious disease therapies.

Vir Biotechnology, Inc. expanded its Board of Directors from seven to eight members and appointed Timothy Coughlin, CPA, to a newly created Class III director seat. Mr. Coughlin will also serve as Chair of the Audit Committee. Vir Biotechnology, Inc. is a biotechnology company focused on developing and commercializing infectious disease therapies.